Literature DB >> 8405326

Apparent polycythaemia: diagnosis, pathogenesis and management.

M Messinezy1, T C Pearson.   

Abstract

The term "apparent polycythaemia" is applied to a group of patients who have a raised PCV (> 0.51 in males, > 0.48 in females) but a normal red cell mass (less than 25% above their predicted mean normal value). Some have additionally a marked reduction in plasma volume and can be defined as a subgroup: relative polycythaemia. Smoking, hypertension and to a lesser extent obesity, excessive alcohol, low-dose diuretic therapy and hypoxaemia have all been associated with apparent polycythaemia but the mechanism is both uncertain and likely to be complex. This group of patients is unlikely to be uniform in pathogenesis and may well include some normal individuals. Investigation requires exclusion of factors associated with other types of polycythaemia. The possibility of an increased vascular occlusive risk is uncertain in these patients except at the higher PCV values. Reduction of PCV by venesection is sensible at PCV > 0.54 or where there is perceived to be an increased risk of vascular occlusion. The remaining patients should be managed by regular observation to detect further rise in PCV or evolution to absolute polycythaemia (raised red cell mass). In some, the PCV returns to normal.

Entities:  

Mesh:

Year:  1993        PMID: 8405326     DOI: 10.1111/j.1600-0609.1993.tb00611.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  3 in total

Review 1.  Current applications of therapeutic phlebotomy.

Authors:  Tarek Bou Assi; Elizabeth Baz
Journal:  Blood Transfus       Date:  2013-10-03       Impact factor: 3.443

2.  A Rare Variant of Wallenberg's Syndrome: Opalski syndrome.

Authors:  Parathan Kk; Kannan R; Chitrambalam P; Senthil Kumar Aiyappan; Deepthi N
Journal:  J Clin Diagn Res       Date:  2014-07-20

3.  Triple-way therapeutic approach for paraganglioma-dependent erythrocytosis: drugs and surgery plus "multi-manner" apheresis.

Authors:  M Todorovic; B Balint; N Suvajdzic; M Jevtic; M Pavlovic; M Petrovic; M Krstic; V Popovic; B Ivanovic; I Elezovic; R Milenkovic; M Colovic
Journal:  Med Oncol       Date:  2007-09-25       Impact factor: 3.064

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.